APS:CC News and Press, Aptose Biosciences Inc.

Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction  TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with divers...

2026-03-31 13:13:18 ET Aptose Biosciences Inc. (APS:CA) Shareholder/Analyst Call March 31, 2026 11:00 AM EDT... Read the full article on Seeking Alpha For further details see: Aptose Biosciences Inc. (APS:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Shareholders are Recommended to Vote “FOR” the Aptose Biosciences Proposed Plan of Arrangement with Hanmi Pharmaceutical Shareholders are Reminded of Voting Deadline for Upcoming Special Meeting SAN DIEGO and TORONTO, March 23, 2026 (GLOBE NEWSWIRE) --  Aptose Biosciences I...

SAN DIEGO and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) today announced that Institutional Shareholder Services (“ISS”), a leading independent proxy advisory firm, has recomm...

SAN DIEGO and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) announced today that it has entered into an amended and restated arrangement agreement dated February 23, 2026 (the “ Amended ...

SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming special meeting of shareholders, originally scheduled to be held on January...

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations Safety continues to be a notable hallmark of TUS-based therapies 100% response rate (CR/CRh) at the two higher dose ...

SAN DIEGO and TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) today announced that Aptose, Hanmi and HS North America Ltd., a wholly owned su...

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now Being Treated at 160 mg Dose of Tuspetinib SAN DIEGO and TORONTO, Nov. 13, 2025 ...

SAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed...